Drugs / PSCA-CAR T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05805371 | Jul 2024 → Nov 2028 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03873805 | Aug 2019 → Aug 2022 overdue | castration-resistant prostate carcinoma, metastatic prostate carcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSCA-CAR T cells | “PSCA-CAR T cells are immune cells that have been engineered in the laboratory to kill tumor cells.” NCT03873805 ↗1“receive PSCA-CAR T cells intravenously (IV) up to 3 times on study.” NCT05805371 ↗ |
| Action | Deplete | “PSCA-CAR T cells are immune cells that have been engineered in the laboratory to kill tumor cells.” NCT03873805 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy is a type of treatment” NCT05805371 ↗ |
| Route | Intravenous | “Patients then receive autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes IV over 10-15 minutes at day 0.” NCT03873805 ↗ |
| Target | PSCA | “PSCA-directed CAR T cells in men with mCRPC.” PMID 38867077 ↗ Jun 2024 |